Stonewise

Executive Summary

Stonewise is a Beijing-based biotechnology company leveraging artificial intelligence and machine learning to accelerate small molecule drug discovery, with a primary focus on oncology and immunology. Founded in 2018, the company has developed a proprietary platform designed to streamline hit-finding and lead optimization for challenging therapeutic targets, aiming to reduce the time and cost of traditional drug development. Operating at a preclinical stage, Stonewise has assembled a team of 50–200 employees and positions itself within the rapidly growing AI-driven drug discovery ecosystem in China. While the company has not publicly disclosed specific pipeline candidates or funding rounds, its platform approach and focus on difficult targets suggest potential for strategic partnerships or milestone achievements in the near term.

Upcoming Catalysts (preview)

• Q3 2026Announcement of lead optimization candidate for an oncology target40% success
• Q1 2027Partnership or collaboration with a major pharmaceutical company30% success
• Q4 2026Series B or later-stage fundraising round50% success